Cannabis Law Report

AUGUST 10, 2021

As psychedelic therapy trials approach FDA approval, researchers express the urgent need to ensure effectiveness and accessibility to communities of color. Madison Natarajan, MS. – August 5, 2021.

Clinical Trials 105

Clinical Trials Research and Development Therapy Treatment 105

Cannabis Law Report

MARCH 30, 2019

Ministry of Health, Labor and Welfare officials recently announced the trials during a meeting of the Okinawa-Northern Task Force, a research and development agency. It was primarily developed for the treatment of two severe forms of epilepsy — Dravet Syndrome and Lennox-Gastaut Syndrome.

Clinical Trials 45

Clinical Trials Research and Development Epilepsy Environment 45

Cannabis Law Report

DECEMBER 27, 2019

Virtual Clinical Trials transcend geographic, mobility and economic barriers. Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.

Clinical Trials 85

Clinical Trials Access Research and Development Supply Chain 85

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Medical Marijuana Program Connection

DECEMBER 5, 2023

SASKATOON, Saskatchewan–(BUSINESS WIRE)– #Phase2–ZYUS Life Sciences Corporation (“ZYUS” or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of. Read More

Clinical Trials 59

Clinical Trials Research and Development Business 59

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

JULY 13, 2022

Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”. VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (

Therapy 52

Therapy Clinical Trials Microdosing Research and Development 52

Cannabis Law Report

JULY 6, 2021

This collaboration is intended to include research into COMP360 psilocybin therapy and other novel therapies that may be developed by COMPASS in areas of unmet need such as depression, post-traumatic stress disorder (PTSD) and anorexia. This is a really exciting prospect and has the potential to change people’s lives for the better.”.

Research and Development 98

Research and Development Clinical Trials Therapy Patients 98

Cannabis Law Report

MAY 29, 2022

is a Canadian company that researches, develops and grows psilocybin-producing mushrooms and functional mushrooms. The psilocybin mushrooms are headed to clinical trials, drug companies and medical facilities. “I’m Optimi Health Corp. I’m excited that we pulled our first crop down.

Research and Development 52

Research and Development Clinical Trials Medicine Access 52

Cannabis Law Report

MAY 12, 2022

Two United States Senators have sent a letter to the leadership of federal agencies asking for an update and pushing for advancement on research into psychedelics. Please provide details on current NIH funding of psychedelic research, including a breakout by institute, and a breakout by basic versus clinical research.

Research and Development 52

Research and Development Clinical Trials Microdosing Food 52

Puff Puff Post

MARCH 10, 2020

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs. Visit [link].

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Veriheal

JULY 16, 2020

The commission tasked with developing recommendations to improve mental health treatment for veterans concluded: Congress and the executive branch need to promote research into the therapeutic potential of cannabis and psychedelics such as psilocybin mushrooms and MDMA. Research is Limited Due to Many Obstacles.

Research and Development 97

Research and Development Clinical Trials Treatment Compliance 97

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

AUGUST 13, 2021

We’re thrilled to be pursuing SalA and progressing research, as we strive for new treatments.”. Importantly, Revixia’s product will be paired with a digital therapeutic being developed by atai company Introspect Digital Therapeutics, with the aim of streamlining preparation, integration, and continued patient engagement. “In

Conditions 105

Conditions Research and Development Clinical Trials Treatment 105

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. About MyMD Pharmaceuticals, Inc. 646) 421-9523.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

SpeedWeed

JULY 23, 2021

Denver is expanding Alzheimer’s research through the efforts of local company MedPharm. . The company plans to move forward with research efforts through a special Schedule I Researcher Licenses given specifically to the company by the Drug Enforcement Administration. Denver Company Moves Forward with Research License .

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

Veriheal

SEPTEMBER 18, 2020

Research Team to Study the Impact of CBD on Spinal Injury Pain. Professor Luke Henderson is set to be the study’s lead investigator and he explains that the unfortunate truth for more than half of spinal cord injury patients is the development of chronic pain. Dr. Carins is a postdoctoral researcher who completed her Ph.D.

Treatment 98

Treatment Chronic Pain Research and Development CBD 98

Cannabis Law Report

JULY 8, 2021

(NYSE American: YCBD, YCBDpA), one of the leading, and most highly trusted and recognized CBD companies, announced today that its recently formed division, cbdMD Therapeutics, has initiated talks with one of the leading US cannabinoid research institutes, to identify novel cannabinoids for therapeutic use. About cbdMD, Inc. cbdMD, Inc.

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

Cannabis Law Report

JULY 27, 2021

.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., as its Research Director, a new role in the organization’s leadership. plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

LifeCannMD

FEBRUARY 27, 2024

Inflammation in the brain is thought to contribute to the development and persistence of seizures. The most compelling evidence of the effectiveness of Medical Marijuana in treating epilepsy comes from clinical trials. Medical Marijuana has been shown to have anti-inflammatory properties.

Clinical Trials 59

Clinical Trials Epilepsy Marijuana Research and Development 59

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

AUGUST 22, 2021

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. OTCQB: SILO), a development-stage biopharmaceutical company focused on the therapeutic potential of psychedelics, recently announced that the U.S. Silo Pharma Inc. Looking to the Future.

Clinical Trials 105

Clinical Trials Research and Development Safety Treatment 105

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

DECEMBER 9, 2021

MindMed presented FDA with a working Indications for Use statement (IFU), and a development roadmap. FDA provided key feedback regarding the draft IFU and the research methods that will lay the foundation for regulatory submissions. ” About MindMed.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

SEPTEMBER 2, 2022

LOBEF signed a deal with Cantheon Capital, a development of cannabinoids and psychedelic drugs supporter, for aggregate proceeds to the company of up to $1.5 Funding for psychedelics research and clinical trials is certainly here to stay. Psychedelics biopharma company Lobe Sciences Ltd.

Clinical Trials 52

Clinical Trials Research and Development Cannabinoids Medicine 52

The Cannigma

JUNE 14, 2021

For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. We are absolutely ecstatic,” George Hodgin, the CEO of the Castroville, California based Biopharmaceutical Research Co. Junk’ cannabis ‘ill-suited for clinical trials’.

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Cannabis Law Report

FEBRUARY 28, 2022

In the past two decades, pioneering research has rekindled interest in the therapeutic use of psychedelic substances such as psilocybin, ibogaine, and dimethyltryptamine (DMT). Indigenous communities have used them for centuries, and researchers studied them in the 1950s and ‘60s. Glenn Cohen & Mason Marks. 20 February 2022.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

AUGUST 7, 2021

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. European Regulatory Lead Executive Summary.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Cannabis Law Report

MARCH 25, 2020

OTCQB: AXIM) (“AXIM® Biotech” or “AXIM”) has completed the acquisition of leading oncology research and development company Sapphire Biotech, Inc. (“Sapphire”). Valencia has stewarded Sapphire in the development of its unique patent-pending pipeline. About AXIM® Biotechnologies.

Research and Development 59

Research and Development Supply Chain Pharmaceutical Clinical Trials 59

Veriheal

MAY 3, 2022

A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research. Clinical Trial Sample Size.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

SEPTEMBER 10, 2021

The announcement of a partnership between Clerkenwell Health and Octarine Bio signals a momentous time for the growth and development of the European psychedelic ecosystem. Clerkenwell Health is a psychedelic specialist clinical research organisation, based in the UK, backed with investment from VC Fund Vine Ventures, and Angel investors.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

DECEMBER 26, 2021

EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial. The Company is pleased to confirm that it is on track to submit its regulatory package to the Dutch ethics committee in early 2022 for its upcoming human trial. . – December 16, 2021) – Entheon Biomedical Corp. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

WeedAdvisor

JULY 4, 2019

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. Lead researcher Sue Sinsley of SRI says: “While most states in the U.S. A Vicious Circle. .

DEA 111

DEA Research and Development Clinical Trials Cultivation 111

Cannabis Law Report

NOVEMBER 1, 2021

In the past few decades, pioneering research has rekindled interest in the therapeutic use of psychedelic substances such as psilocybin, ibogaine, and dimethyltryptamine (DMT). Indigenous communities have used them for centuries, and researchers studied them in the 1950s and 60s. Date Written: October 23, 2021. war on drugs.

Research and Development 52

Research and Development Law Clinical Trials Therapy 52

Veriheal

FEBRUARY 9, 2023

Now, Australian researchers think they may have found an answer: taking psilocybin before MRIs. A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. Magic Mushrooms: The Ticket to a Stress-Free MRI?

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98